Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

TEM vs DOCS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DOCS Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

DOCS Overall Winner 6-Pillar Tally: TEM 2 – 4 DOCS Matrix Metrics: TEM 3 – 7 DOCS

As of Nov 17, 2026, Doximity, Inc. (DOCS) is the stronger overall head-to-head candidate over Tempus AI, Inc. (TEM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). TEM carries a Unified Composite Score of 43.5/100 (HOLD) at $63.08 (N/M Forward P/E, -18.5% operating margin), whereas DOCS carries 56.2/100 (HOLD) at $31.25 (20.2x Forward P/E, 27.1% operating margin).

  • Growth vs. Quality Trade-Off: DOCS earns the overall head-to-head edge with a stronger Unified Composite Score (56.2/100 HOLD vs. TEM 43.5/100 HOLD) and 0.68β · 42% Vol risk profile, whereas TEM leads top-line expansion (+23.1% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: TEM is currently in a Breakdown options structure phase (RSI 40.3); meanwhile DOCS trades in a Neutral technical trend (SURGE options phase, RSI 46.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TEM vs DOCS
TEM NASDAQ
Tempus AI, Inc. Class A Common Stock
Services-Computer Programming, Data Processing, Etc.
$63.08
-2.59% 1D
Market Cap $13.1B
TTM Revenue $1.51B
Forward P/E N/M
Beta / 30D Vol 2.51β · 93% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 31.0 Fund 51.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 40
RSI-14: 40.3 · SMA20: $73.18 · SMA50: $72.83
DOCS NYSE Head-to-Head Winner
Doximity, Inc.
Services-Computer Programming Services
$31.25
-4.62% 1D
Market Cap $5.9B
TTM Revenue $662M
Forward P/E 20.2x
Beta / 30D Vol 0.68β · 42% Vol
Unified Composite Score
56.2 / 100 HOLD
Tech 40.0 Fund 51.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.3 · SMA20: $33.13 · SMA50: $30.00

6-Pillar Scorecard Institutional Category Breakdown (TEM 2 – 4 DOCS)

Columns: Metric · TEM · DOCS
1. Valuation Multiples DOCS
Forward P/E N/M 20.2x
Trailing P/E N/M 46.3x
PEG Ratio N/M 0.59x
EV / Revenue 9.2x 8.7x
2. Growth & Scale TEM
Revenue Growth (YoY) +23.1% +3.6%
Earnings Growth (YoY) +0.0% -41.9%
TTM Revenue (USD) $1.51B $662M
Market Cap $13.1B $5.9B
3. Profitability & Quality DOCS
Gross Margin 64.5% 86.8%
Operating Margin -18.5% 27.1%
Net Profit Margin -12.5% 21.1%
Return on Equity (ROE) -37.5% 13.8%
4. Balance Sheet & Cash Flow DOCS
Cash Generation (TTM) -$151M $297M
Cash Flow Margin -10.0% 44.9%
Net Cash / Leverage $841M Net Debt (2.86x D/E) $209M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DOCS
Options Structure Phase BREAKDOWN SURGE
Current IV / %ile 99.3% (44th %ile) 42.5% (33rd %ile)
Put/Call OI Skew 0.49x (Call-Skewed) 0.25x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat TEM
OpEx & R&D Intensity 83.0% of Rev ($1.25B) 59.7% of Rev ($395M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Ecosystem & Network-Effect Moat Scale & Operating Efficiency Moat
Supply-Chain Role Health Information Services Operator Health Information Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TEM (3) vs DOCS (7)
Institutional Metric TEM DOCS Criterion Row Edge
Market Capitalization
Scale
$13.1B $5.9B Larger Scale TEM
Trailing P/E Ratio
Valuation
N/M 46.3x Lower Multiple DOCS
Forward P/E Ratio
Valuation
N/M 20.2x Lower Multiple DOCS
Revenue Growth (YoY)
Growth
+23.1% +3.6% Higher Growth TEM
Operating Margin (TTM)
Profitability
-18.5% 27.1% Higher Margin DOCS
Net Profit Margin
Profitability
-12.5% 21.1% Higher Margin DOCS
Return on Equity (ROE)
Capital Efficiency
-37.5% 13.8% Higher ROE DOCS
52-Week Range Position
Momentum
46% ($41–$89) 41% ($17–$52) Stronger Trend TEM
Beta / 30D Volatility
Risk Regime
2.51β · 93% Vol 0.68β · 42% Vol Lower Realized Risk DOCS
Unified Institutional Score
Composite Signal
43.5 / 100 (HOLD) 56.2 / 100 (HOLD) Higher Composite DOCS
Trailing 12M Revenue (USD)
Operating Scale
$1.51B $662M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.5% 86.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.2x EV/Rev 0.59x PEG · 8.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$151M ($841M Net Debt (2.86x D/E)) $297M ($209M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DOCS +1.34 pp
TEM: -1.96% · DOCS: -0.62%
3M Horizon DOCS +18.39 pp
TEM: +2.99% · DOCS: +21.38%
6M Horizon DOCS +23.73 pp
TEM: +38.55% · DOCS: +62.28%
1Y Horizon TEM +29.12 pp
TEM: -7.89% · DOCS: -37.01%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period TEM Revenue DOCS Revenue TEM Op. Margin DOCS Op. Margin Margin Leader
FY2020 N/A $120M N/A 19.0% DOCS
FY2021 N/A $210M N/A 25.8% DOCS
FY2022 $320M $340M -82.8% 33.0% DOCS
FY2023 $530M $420M -36.9% 29.9% DOCS
FY2024 $690M $480M -99.7% 34.5% DOCS
FY2025 $1.27B $570M -19.9% 39.9% DOCS
FY2026 N/A $640M N/A 33.3% DOCS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TEM BREAKDOWN
36d in phase · OBV DISTRIBUTION
Current IV 99.3%
IV Percentile 44th %ile
Put/Call OI Skew 0.49x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact TEM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DOCS SURGE
14d in phase · OBV NEUTRAL
Current IV 42.5%
IV Percentile 33rd %ile
Put/Call OI Skew 0.25x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DOCS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $64.76 · IV 84.1%

TEM vs. DOCS: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of TEM ($6,476) vs. DOCS ($3,277) against risk-defined 5-day vertical and put-wall option structures.

TEM Spot $64.76 · IV 84.1%
TEM Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $65 / $75 Bull Call Spread

Buy 1x $65C · Sell 1x $75C · 32d

Net Entry $365 Debit
T+5d @ +5% Move +$69 (+19%)
Max Risk / Buffer $365 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $60 / $55 Bull Put Spread

Sell 1x $60P · Buy 1x $55P · 32d

Net Entry $160 Credit
Max Credit / Yield +$160 (+47.1% RoM)
Max Risk / Buffer -9.8% Cushion ($340 Mgn)
5d Edge & Liquidity 68% PoP · Liq A
Simulate 5-Day Payoff →
DOCS Spot $32.77 · IV 42.9%
DOCS Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $32.5 / $35 Bull Call Spread

Buy 1x $32.5C · Sell 1x $35C · 32d

Net Entry $90 Debit
T+5d @ +5% Move +$41 (+46%)
Max Risk / Buffer $90 Capped
5d Edge & Liquidity 0.9x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $30 / $27.5 Bull Put Spread

Sell 2x $30P · Buy 2x $27.5P · 32d

Net Entry $58 Credit
Max Credit / Yield +$58 (+13.1% RoM)
Max Risk / Buffer -9.3% Cushion ($442 Mgn)
5d Edge & Liquidity 79% PoP · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TEM Moat Profile Ecosystem & Network-Effect Moat
Health Information Services Operator
Competes within the Health Information Services value chain with $13.1B market capitalization and -18.5% operating margin.
OpEx & R&D Reinvestment 83.0% of Rev ($1.25B)
90D Engineering Disclosures 0 Published · AI Drug Discovery
DOCS Moat Profile Scale & Operating Efficiency Moat
Health Information Services Operator
Competes within the Health Information Services value chain with $5.9B market capitalization and 27.1% operating margin.
OpEx & R&D Reinvestment 59.7% of Rev ($395M)
90D Engineering Disclosures 0 Published

Investor FAQ TEM vs DOCS Key Questions & Quantitative Answers

As of Nov 17, 2026, Doximity, Inc. (DOCS) is the stronger overall head-to-head candidate over Tempus AI, Inc. (TEM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). TEM carries a Unified Composite Score of 43.5/100 (HOLD) at $63.08 (N/M Forward P/E, -18.5% operating margin), whereas DOCS carries 56.2/100 (HOLD) at $31.25 (20.2x Forward P/E, 27.1% operating margin). Growth vs. Quality Trade-Off: DOCS earns the overall head-to-head edge with a stronger Unified Composite Score (56.2/100 HOLD vs. TEM 43.5/100 HOLD) and 0.68β · 42% Vol risk profile, whereas TEM leads top-line expansion (+23.1% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: TEM is currently in a Breakdown options structure phase (RSI 40.3); meanwhile DOCS trades in a Neutral technical trend (SURGE options phase, RSI 46.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TEM leads the Growth & Scale pillar: TEM posts +23.1% YoY revenue growth and +0.0% YoY earnings growth on $1.51B TTM revenue (64.5% gross margin, -18.5% operating margin), compared with DOCS at +3.6% YoY revenue growth and -41.9% YoY earnings growth on $662M TTM revenue (86.8% gross margin, 27.1% operating margin). Across the 7-period historical trajectory (FY2020 to FY2026), TEM cumulative revenue shifted +296.9% while DOCS shifted +433.3%. In operating R&D and SG&A reinvestment, TEM deploys 83.0% of Rev ($1.25B) (0 90-day corporate R&D disclosures) versus 59.7% of Rev ($395M) (0 disclosures) for DOCS.

DOCS screens cheaper on headline valuation multiples. TEM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.2x EV/Revenue (-10.0% FCF margin), whereas DOCS trades at 20.2x Forward P/E, 46.3x Trailing P/E, 0.59x PEG, and 8.7x EV/Revenue (44.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TEM (-37.5% ROE) versus DOCS (13.8% ROE) capital efficiency.

In options market volatility and institutional positioning, TEM carries 99.3% implied volatility (44th %ile, Balanced (25th–60th %ile)), a 0.49x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.51β · 93% Vol realized risk). By comparison, DOCS carries 42.5% implied volatility (33rd %ile, Balanced (25th–60th %ile)), a 0.25x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.68β · 42% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.